Non-cannabinoid constituents from a high potency Cannabis sativa variety

Radwan, MM; ElSohly, M. A.; Slade, Desmond; Ahmed, Sohail; Wilson, Lisa; Al-Alfy, A. T.; Ross, Samir A.

doi:10.1055/s-0028-1084474

Cited by 16 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antileishmanial activity for cannflavin B (the double bond between C-2 and C-3, C-6 prenyl, 5 mM) has also been observed (Radwan et al 2008b). Radwan et al (2008a) also reported a moderate activity of cannflavin A (17 mg/mL, 39 mM). Salem et al (2011) have published some data about the antileishmanial activity of the C-geranyl flavonoids that are in good agreement with the data presented here.…”

Section: Resultsmentioning

confidence: 91%

“…The activity of 3 0 -O-methyl substituted dihydroflavonol 3 was diminished probably due to the presence of 3-OH substitution. C-6-Substituted compounds isolated from C. sativa such as cannflavin C are structurally very similar to compound 4 (except for the double bond between C-2 and C-3), and they have been reported to show an IC 50 value of 4.5 mg/mL (cannflavin C, close to 10 mM) against L. donovani (Radwan et al 2008a). Antileishmanial activity for cannflavin B (the double bond between C-2 and C-3, C-6 prenyl, 5 mM) has also been observed (Radwan et al 2008b).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

C-Geranylated flavonoids fromPaulownia tomentosafruits with antimicrobial potential and synergistic activity with antibiotics

Navrátilová

Nešuta

Vančatová

et al. 2016

Pharmaceutical Biology

View full text Add to dashboard Cite

Context C-6-Geranylated flavonoids possess promising biological activities. These substances could be a source of lead compounds for the development of therapeutics. Objective The study was designed to evaluate their antibacterial and antileishmanial activity. Materials and methods C-6-Geranylated flavanones were tested in micromolar concentrations against promastigote forms of Leishmania brazilensis, L. donovani, L. infantum, and L. panamensis against methicillin-resistant Staphylococcus aureus (MRSA); and synergistic potential with antibiotics was analyzed. IC50 values (after 72 h) were calculated and compared with that of miltefosine. Flow cytometry and DNA fragmentation analysis were used the mechanism of the effect. Geranylated flavanones or epigallocatechin gallate were combined with oxacillin, tetracycline, and ciprofloxacin, and the effects of these two-component combinations were evaluated. Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were established (after 24 h), the synergy was measured by the checkerboard titration technique, and the sums of the fractional inhibitory concentrations (∑FICs) were computed. Results 3'-O-Methyl-5'-O-methyldiplacone and 3'-O-methyldiplacone showed good antileishmanial activities (IC50 8-42 μM). 3'-O-Methyl-5'-hydroxydiplacone activates the apoptotic death at leishmanias, the effect of 3'-O-methyl-5'-O-methyldiplacone has another mechanism. The test of the antibacterial activity showed good effects of 3'-O-methyldiplacol and mimulone against MRSA (MIC 2-16 μg/mL), and in six cases, the results showed synergistic effects when combined with oxacillin. Synergistic effects were also found for the combination of epigallocatechin gallate with tetracycline or oxacillin. Conclusion This work demonstrates anti-MRSA and antileishmanial potential of geranylated flavanones and uncovers their promising synergistic activities with antibiotics. In addition, the mechanism of antileishmanial effect is proposed.

show abstract

Section: Resultsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

C-Geranylated flavonoids fromPaulownia tomentosafruits with antimicrobial potential and synergistic activity with antibiotics

Navrátilová

Nešuta

Vančatová

et al. 2016

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…18 More than 500 constituents have been identified in C. sativa. [18][19][20][21][22][23] C21 terpenophenolic cannabinoids are the most common and extensively studied class of cannabis constituents. The term cannabinoids represents a group of compounds found distinctively in C. sativa.…”

Section: Phytochemistrymentioning

confidence: 99%

“…25 The number of natural compounds identified in C. sativa is continuously increasing; for example, there were 423 in 1980, 26 483 in 1995 23 and more than 525 in 2008. [18][19][20][21][22][23] Described below is a brief overview of the phytochemical aspects of C. sativa, with special focus on the psychoactive components (e.g., cannabinoids).…”

Section: Phytochemistrymentioning

confidence: 99%

Cannabis: A Prehistoric Remedy for the Deficits of Existing and Emerging Anticancer Therapies

Nasir¹,

Fatima²,

Ahmed³

et al. 2017

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

Cannabis in both its pure and altered forms has been beneficial for human use since antiquity. 1 Members of the genus Cannabis mostly produce dioecious annual herbs. 2,3 The exact number of Cannabis species is a point of great debate, as according to different researchers there are variable number of species. 4-10 The species that are most pertinent include, Cannabis sativa, Cannabis ruderalis and Cannabis indica. However, among these, the highly polymorphic species Cannabis sativa L. is considered as the most active, based on studies targeting its morphology, anatomy, phyto-chemistry and genetics. 11 The morphological diversity of this plant is phenomenal, and it has tremendous potential as foodstuff and fuel (edible food/oil from its achene), fibre (stem) and pharmaceuticals. It also has unrivalled biochemical riches with regard to its considerable balance of active and biologically significant compounds and their potential medical uses. 12 History The history of C. sativa use dates back to over 10,000 years, supporting its recognition as one of the oldest domestic plants known to humanity. 7,13 It originated from Central Asia and is one of the oldest known psychotropic drugs. C. sativa was cultivated and consumed long before civilization; therefore, uncovering the origin of its use by humans is a difficult task. Archaeological discoveries have shown that it has been recognized and acknowledged since the Neolithic era in China, (around 4000 BC). 13 However the psychoactive potential of this plant was recognized by western medicine quite latter, with the year of 1839 seeing the first of its real description of actions. 14 China's Emperor Shen Nung wrote in his 2737 BC compendium the first description of the properties and medicinal uses of C. sativa. 14 Subsequently, it was cultivated for its fibre, fuel, seeds and medicinal purposes. 11 A distinguished surgeon in ancient China, Hua Tuo (115-205 AD), reportedly used cannabis as an anaesthetic. The analgesic and anaesthetic tendencies of C. sativa were also revealed in the biography of Chinese physician Hoa-tho, who practiced around 220 AD. 15 C. sativa then spread to the rest of the world, to ancient Egypt, prehistoric Europe, ancient Greece and

show abstract

“…These two compounds occur in high amounts in most cannabis strains, either with a predominance of one over the other or with relatively equal amounts. This relative amount allows a differentiation between two main groups, one mostly diagnosed as "high in THC", which are related to sativa-originated strains and the other, "high in CBD" that are more indica-related strains [26]. However, over the last decade, many more phytocannabinoids were identified and their structure was more thoroughly studied [2,[26][27][28].…”

mentioning

confidence: 99%

Medical Cannabis for the Treatment of Inflammation

Namdar

Koltai

2018

Natural Product Communications

View full text Add to dashboard Cite

The connection between Cannabis sativa's chemical compounds and their ability to treat three different inflammatory ailments including bowel diseases, (IBD, e.g., Crohn's and ulcerative colitis), neuronal diseases (IND, e.g., Parkinson and Alzheimer), and a wide range of inflammatory skin diseases (ISD, e.g., atopic dermatitis and psoriasis) is presented. We review the range of experiments conducted over the last decade using either the whole extract of cannabis or separated mono-phytocannabinoids in the attempt to decipher the lead molecules, the receptors involved, the effects on genes and proteins, and especially the therapeutic potency of cannabis-derived compounds for treating these different inflammatory diseases. Along with the specifications for its current cuttingedge potential, the drawbacks and the designated needs for additional specific information from future research are indicated.

show abstract

Non-cannabinoid constituents from a high potency Cannabis sativa variety

Cited by 16 publications

References 14 publications

C-Geranylated flavonoids fromPaulownia tomentosafruits with antimicrobial potential and synergistic activity with antibiotics

C-Geranylated flavonoids fromPaulownia tomentosafruits with antimicrobial potential and synergistic activity with antibiotics

Cannabis: A Prehistoric Remedy for the Deficits of Existing and Emerging Anticancer Therapies

Medical Cannabis for the Treatment of Inflammation

Contact Info

Product

Resources

About